CompanyGraph
Guangzhou Kingmed Diagnostics Group Co. Ltd.
603882 · SSE · China
kingmed.com.cnFinancials as of FY2025
At a glance
- Depends onMidstream position: 6 outgoing, 6 incoming connections
- ScaleMarket cap is $2.12B, above the global median of $1.15B
- FinancialsAltman Z-Score 4.96: safe zone
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
2.81%Above 5Y avg (2.63%)
Annual Rate
CNY 0.88Paid annual
Payout Ratio
251.4%High
Payback Period
35.6 yr
Last Ex-Dividend
Feb 5, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
14.25BCNY2.12B · vs all stocks (USD)
Revenue (TTM)
5.91BCNY879.61M · vs all stocks (USD)
Profit Margin
-1.74%vs Diagnostics & Research peers
Beta
0.3730xvs all stocks
52-Week Change
-0.76%vs all stocks
Market Capitalization
14.25BCNY2.12B · vs all stocks (USD)
Enterprise Value
11.60BCNY1.72B · vs all stocks (USD)
Forward P/E
26.52xvs Diagnostics & Research peers
Price to Sales (TTM)
2.41xvs Diagnostics & Research peers
Price to Book (MRQ)
2.24xvs Diagnostics & Research peers
Enterprise to Revenue
1.96xvs Diagnostics & Research peers
Enterprise to EBITDA
47.90xvs Diagnostics & Research peers
Gross Margin
34.90%vs Diagnostics & Research peers
Profit Margin
-1.74%vs Diagnostics & Research peers
Operating Margin
5.44%vs Diagnostics & Research peers
Return on Assets (TTM)
-0.28%vs Diagnostics & Research peers
Return on Equity (TTM)
-1.42%vs Diagnostics & Research peers
Revenue (TTM)
5.91BCNY879.61M · vs all stocks (USD)
Revenue per Share (TTM)
12.55CNYUpdated Aug 21, 2026Quarterly Revenue Growth
-7.90%vs Diagnostics & Research peers
Gross Profit (TTM)
2.08BCNY309.15M · vs all stocks (USD)
EBITDA (TTM)
627.28MCNY93.28M · vs all stocks (USD)
Net Income (TTM)
-102.67MCNY-15.27M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-13.99%vs Diagnostics & Research peers
Operating Cash Flow (TTM)
1.19BCNY177.10M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
815.37MCNY121.25M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.8800CNYUpdated Aug 21, 2026Trailing Annual Dividend Yield
2.81%vs all stocks
5-Year Average Dividend Yield
2.63%vs all stocks
Payout Ratio
251.43%vs Diagnostics & Research peers
Minority Interest (Equity)
129.16MCNYFY2025 · Dec 31, 2025Revenue
6.03BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
3.94BCNYFY2025 · Dec 31, 2025Gross Profit
2.10BCNYFY2025 · Dec 31, 2025Operating Income
242.30MCNY36.03M · vs all stocks (USD)
Pre-tax Income
-181.61MCNYFY2025 · Dec 31, 2025Income Tax Expense
-3.01MCNYFY2025 · Dec 31, 2025Net Income
-178.60MCNYFY2025 · Dec 31, 2025EBIT
-166.93MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
627.28MCNYFY2025 · Dec 31, 2025Research & Development
341.28MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
586.01MCNYFY2025 · Dec 31, 2025Other Operating Expenses
13.94MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
20.51MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
14.68MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.3700CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.3700CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
468.23MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
468.23MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-178.60MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
5.36MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
602.71MCNYFY2025 · Dec 31, 2025Free Cash Flow
198.88MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
2.85BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-178.60MCNYFY2025 · Dec 31, 2025Other Non-cash Items
102.94MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
742.60MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-64.23MCNYFY2025 · Dec 31, 2025Capital Expenditures
-403.83MCNYFY2025 · Dec 31, 2025Purchase of Investments
-46.95MCNYFY2025 · Dec 31, 2025Sale of Investments
79.80MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-370.97MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
221.89MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-87.49MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-413.90MCNYFY2025 · Dec 31, 2025Other Financing Charges
-94.47MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-373.97MCNYFY2025 · Dec 31, 2025Shares Outstanding
463.26MSharesUpdated Aug 21, 2026Float Shares
284.72MSharesUpdated Aug 21, 2026% Held by Insiders
42.42%vs all stocks
% Held by Institutions
9.93%vs all stocks
Total Cash (MRQ)
2.35BCNY349.26M · vs all stocks (USD)
Total Cash per Share (MRQ)
5.07CNYUpdated Aug 21, 2026Total Debt (MRQ)
857.77MCNY127.56M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.1323xvs Diagnostics & Research peers
Current Ratio (MRQ)
3.13xvs Diagnostics & Research peers
Book Value per Share (MRQ)
13.71CNYUpdated Aug 21, 2026Total Assets
9.60BCNY1.43B · vs all stocks (USD)
Total Current Assets
6.61BCNYFY2025 · Dec 31, 2025Total Liabilities
2.75BCNYFY2025 · Dec 31, 2025Total Non-current Assets
2.99BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
703.83MCNYFY2025 · Dec 31, 2025Total Current Liabilities
2.04BCNYFY2025 · Dec 31, 2025Cash
2.85BCNYFY2025 · Dec 31, 2025Cash Equivalents
5.63MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
2.85BCNYFY2025 · Dec 31, 2025Accounts Receivable
3.35BCNYFY2025 · Dec 31, 2025Inventory
186.10MCNYFY2025 · Dec 31, 2025Accounts Payable
1.49BCNYFY2025 · Dec 31, 2025Short-term Debt
167.27MCNYFY2025 · Dec 31, 2025Other Current Liabilities
338.27KCNYFY2025 · Dec 31, 2025Long-term Debt
668.38MCNYFY2025 · Dec 31, 2025Common Stock (Book)
463.26MCNYFY2025 · Dec 31, 2025Retained Earnings
4.84BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
6.86BCNY1.02B · vs all stocks (USD)
52-Week Low
21.50CNYUpdated Aug 21, 202652-Week High
40.68CNYUpdated Aug 21, 202652-Week Change
-0.76%vs all stocks
Beta
0.3730xvs all stocks
50-Day MA
26.12CNYUpdated Aug 21, 2026200-Day MA
28.12CNYUpdated Aug 21, 2026Avg 10-Day Volume
14.14MSharesUpdated Aug 21, 2026Avg 30-Day Volume
11.35MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
-0.2200CNYUpdated Aug 21, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 4.96: safe zoneNotable
Altman Z-Score: 4.96
Supply Chain
Midstream position: 6 outgoing, 6 incoming connectionsNotable
Outgoing: 6.00Incoming: 6.00
High connectivity hub: 12 industry connectionsNotable
Total Connections: 12.00
Scale
Market cap is $2.12B, above the global median of $1.15BNotable
Market cap (USD): 2,119,091,407.195Global Median: 1,146,734,693.424
Revenue is $879.61M, above the global median of $520.53MNotable
Revenue (USD): 879,608,581.217Global Median: 520,528,949.311
Levered free cash flow is $121.25M, above the global median of $16.24MNotable
Levered free cash flow (USD): 121,253,184.931Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Fujian Kuncai Material Technology Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowSenseMaking
Wuxi Huaguang Environment Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionRuleSenseMaking
Sineng Electric Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionRuleFlow
Shriram Pistons & Rings Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowRule
China Automotive Engineering Corporation
Tier 1ProductionThroughput-Bound ConversionSenseMakingRule
5N Plus Inc.
Tier 1ProductionThroughput-Bound ConversionSenseMakingFlow
Shanghai Feilo Acoustics Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionRuleSenseMaking
Biem.Lfdlkk Garment Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowAttention
Shenyang Xingqi Pharmaceutical Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionRule
Zhejiang Xinan Chemical Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionRuleFlow